116 related articles for article (PubMed ID: 18778887)
1. Successful treatment with weekly paclitaxel and carboplatin combined with trastuzumab in a patient with heavily pretreated metastatic breast cancer.
Kikuchi Y; Takano M; Kudoh K; Kita T; Sato K
Eur J Obstet Gynecol Reprod Biol; 2008 Dec; 141(2):189-91. PubMed ID: 18778887
[No Abstract] [Full Text] [Related]
2. Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer.
Burris H; Yardley D; Jones S; Houston G; Broome C; Thompson D; Greco FA; White M; Hainsworth J
J Clin Oncol; 2004 May; 22(9):1621-9. PubMed ID: 15117984
[TBL] [Abstract][Full Text] [Related]
3. Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252.
Perez EA; Suman VJ; Rowland KM; Ingle JN; Salim M; Loprinzi CL; Flynn PJ; Mailliard JA; Kardinal CG; Krook JE; Thrower AR; Visscher DW; Jenkins RB
Clin Breast Cancer; 2005 Dec; 6(5):425-32. PubMed ID: 16381626
[TBL] [Abstract][Full Text] [Related]
4. [Markedly effective regimen using bi-weekly trastuzumab and paclitaxel in an advanced breast cancer with multiple liver metastases].
Rai Y; Takahama T; Sagara Y; Sagara Y; Matsuyama Y; Ando M; Sagara Y; Ooi Y
Gan To Kagaku Ryoho; 2006 Sep; 33(9):1297-300. PubMed ID: 16969028
[TBL] [Abstract][Full Text] [Related]
5. [Preoperative therapy with trastuzumab and paclitaxel in a stage IV advanced breast cancer with complete pathologic response].
Rai Y; Sagara Y; Sagara Y; Takahama T; Matsuyama Y; Ando M; Sagara Y; Ooi Y; Inoue K; Kurosumi M
Gan To Kagaku Ryoho; 2007 Jan; 34(1):65-8. PubMed ID: 17220672
[TBL] [Abstract][Full Text] [Related]
6. [Two cases of recurrent breast cancer with regional lymph node metastases showing a complete response to trastuzumab and paclitaxel treatment].
Ohsako T; Inoue K; Nagamoto N; Yoshida Y; Nakahara O
Gan To Kagaku Ryoho; 2006 Sep; 33(9):1301-3. PubMed ID: 16969029
[TBL] [Abstract][Full Text] [Related]
7. [Metastatic breast cancer treated with trastuzumab and paclitaxel--a case report with clinically complete response].
Yoshida T; Horiguchi J; Koibuchi Y; Kanoh T; Iijima K; Yoshida M; Kikuchi M; Takata D; Oyama T; Iino Y; Morishita Y
Gan To Kagaku Ryoho; 2004 Jun; 31(6):907-10. PubMed ID: 15222110
[TBL] [Abstract][Full Text] [Related]
8. [A case of multi-drug resistant recurrent breast cancer with multiple bone metastasis responding to TS-1 and trastuzumab].
Nakajima H; Mizuta N; Mizuta M; Nakatsukasa K; Kobayashi A; Hachimine Y; Sakaguchi K; Fujiwara I; Sawai K
Gan To Kagaku Ryoho; 2006 Sep; 33(9):1305-8. PubMed ID: 16969030
[TBL] [Abstract][Full Text] [Related]
9. Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer.
Gasparini G; Gion M; Mariani L; Papaldo P; Crivellari D; Filippelli G; Morabito A; Silingardi V; Torino F; Spada A; Zancan M; De Sio L; Caputo A; Cognetti F; Lambiase A; Amadori D
Breast Cancer Res Treat; 2007 Mar; 101(3):355-65. PubMed ID: 16850247
[TBL] [Abstract][Full Text] [Related]
10. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer.
Robert N; Leyland-Jones B; Asmar L; Belt R; Ilegbodu D; Loesch D; Raju R; Valentine E; Sayre R; Cobleigh M; Albain K; McCullough C; Fuchs L; Slamon D
J Clin Oncol; 2006 Jun; 24(18):2786-92. PubMed ID: 16782917
[TBL] [Abstract][Full Text] [Related]
11. [Case report of advanced breast cancer responding to capecitabine and trastuzumab combination therapy].
Yoshidome K; Imabun S; Nakahara M; Hiraoka K; Yamagami Y; Tsujimoto M; Nakao K
Gan To Kagaku Ryoho; 2006 Oct; 33(10):1453-6. PubMed ID: 17033236
[TBL] [Abstract][Full Text] [Related]
12. Prolonged administration of weekly paclitaxel and trastuzumab in patients with advanced breast cancer.
Christodoulou C; Klouvas G; Pateli A; Mellou S; Sgouros J; Skarlos DV
Anticancer Res; 2003; 23(1B):737-44. PubMed ID: 12680177
[TBL] [Abstract][Full Text] [Related]
13. Magnetic resonance imaging in predicting pathological response of triple negative breast cancer following neoadjuvant chemotherapy.
Chen JH; Mehta RS; Carpenter PM; Nalcioglu O; Su MY
J Clin Oncol; 2007 Dec; 25(35):5667-9. PubMed ID: 18065744
[No Abstract] [Full Text] [Related]
14. A case of HER2-positive male breast cancer with lung metastases showing a good response to trastuzumab and paclitaxel treatment.
Hayashi H; Kimura M; Yoshimoto N; Tsuzuki M; Tsunoda N; Fujita T; Yamashita T; Iwata H
Breast Cancer; 2009; 16(2):136-40. PubMed ID: 18548321
[TBL] [Abstract][Full Text] [Related]
15. [Effective combination chemotherapy using weekly trastuzumab and paclitaxel in the treatment of a recurrent breast cancer patient with liver metastases].
Tohnosu N; Kobayashi Y; Saito T; Shimizu T; Natsume T; Tanaka H; Maruyama T; Watanabe Y
Gan To Kagaku Ryoho; 2003 Jul; 30(7):989-92. PubMed ID: 12894716
[TBL] [Abstract][Full Text] [Related]
16. [Preoperative therapy using trastuzumab and weekly paclitaxel in a stage IIIB inoperable locally advanced HER2- positive breast cancer with complete pathologic response].
Rai Y; Sagara Y; Ooi Y; Sagara Y; Sagara Y; Baba S; Tamada S; Matsuyama Y; Ando M
Gan To Kagaku Ryoho; 2009 Mar; 36(3):471-3. PubMed ID: 19295274
[TBL] [Abstract][Full Text] [Related]
17. [Bi-weekly nab-paclitaxel and trastuzumab therapy effective against recurrent breast cancer with multiple lung metastases in elderly patient who had previously undergone two chemotherapeutic regimens for treatment of metastatic disease-a case Report].
Sakurai T; Jinta E; Suzuma T; Yoshimura G; Umemura T; Sakurai T
Gan To Kagaku Ryoho; 2012 Nov; 39(11):1703-6. PubMed ID: 23152023
[TBL] [Abstract][Full Text] [Related]
18. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840.
Seidman AD; Berry D; Cirrincione C; Harris L; Muss H; Marcom PK; Gipson G; Burstein H; Lake D; Shapiro CL; Ungaro P; Norton L; Winer E; Hudis C
J Clin Oncol; 2008 Apr; 26(10):1642-9. PubMed ID: 18375893
[TBL] [Abstract][Full Text] [Related]
19. Why adjuvant trastuzumab led to better outcomes in women with high-risk HER-2-positive breast cancer.
Altundag K; Baptista MZ
Breast J; 2006; 12(5):497-8. PubMed ID: 16958977
[No Abstract] [Full Text] [Related]
20. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
Untch M; Fasching PA; Konecny GE; Hasmüller S; Lebeau A; Kreienberg R; Camara O; Müller V; du Bois A; Kühn T; Stickeler E; Harbeck N; Höss C; Kahlert S; Beck T; Fett W; Mehta KM; von Minckwitz G; Loibl S
J Clin Oncol; 2011 Sep; 29(25):3351-7. PubMed ID: 21788566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
